Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection

Jose A VazquezDivision of Infectious Diseases, Henry Ford Hospital, Wayne State University School of Medicine, Detroit, MI, USAAbstract: Mucocutaneous candidiasis is frequently one of the f irst signs of human immunodeficiency virus (HIV) infection. Over 90% of patients with AIDS will develop oropha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Jose A Vazquez
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/d7d735c98a554681a08b12e8d0ddfc08
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d7d735c98a554681a08b12e8d0ddfc08
record_format	dspace
spelling	oai:doaj.org-article:d7d735c98a554681a08b12e8d0ddfc082021-12-02T06:17:40ZOptimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection1179-1373https://doaj.org/article/d7d735c98a554681a08b12e8d0ddfc082010-04-01T00:00:00Zhttp://www.dovepress.com/optimal-management-of-oropharyngeal-and-esophageal-candidiasis-in-pati-a4325https://doaj.org/toc/1179-1373Jose A VazquezDivision of Infectious Diseases, Henry Ford Hospital, Wayne State University School of Medicine, Detroit, MI, USAAbstract: Mucocutaneous candidiasis is frequently one of the f irst signs of human immunodeficiency virus (HIV) infection. Over 90% of patients with AIDS will develop oropharyngeal candidiasis (OPC) at some time during their illness. Although numerous antifungal agents are available, azoles, both topical (clotrimazole) and systemic (fluconazole, itraconazole, voriconazole, posaconazole) have replaced older topical antifungals (gentian violet and nystatin) in the management of oropharyngeal candidiasis in these patients. The systemic azoles, are generally safe and effective agents in HIV-infected patients with oropharyngeal candidiasis. A constant concern in these patients is relapse, which is dependent on the degree of immunosuppression commonly seen after topical therapy, rather than with systemic azole therapy. Candida esophagitis (CE) is also an important concern since it occurs in more than 10% of patients with AIDS and can lead to a decrease in oral intake and associated weight loss. Fluconazole has become the most widely used antifungal in the management of mucosal candidiasis. However, itraconazole and posaconazole have similar clinical response rates as fluconazole and are also effective alternative agents. In patients with fluconazole-refractory mucosal candidiasis, treatment options now include itraconazole solution, voriconazole, posaconazole, and the newer echinocandins (caspofungin, micafungin, and anidulafungin).Keywords: oropharyngeal candidiasis, esophageal candidiasis, HAART, antifungal agents, HIV, AIDS Jose A VazquezDove Medical PressarticleImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol 2010, Iss default, Pp 89-101 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607
spellingShingle	Immunologic diseases. Allergy RC581-607 Jose A Vazquez Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection
description	Jose A VazquezDivision of Infectious Diseases, Henry Ford Hospital, Wayne State University School of Medicine, Detroit, MI, USAAbstract: Mucocutaneous candidiasis is frequently one of the f irst signs of human immunodeficiency virus (HIV) infection. Over 90% of patients with AIDS will develop oropharyngeal candidiasis (OPC) at some time during their illness. Although numerous antifungal agents are available, azoles, both topical (clotrimazole) and systemic (fluconazole, itraconazole, voriconazole, posaconazole) have replaced older topical antifungals (gentian violet and nystatin) in the management of oropharyngeal candidiasis in these patients. The systemic azoles, are generally safe and effective agents in HIV-infected patients with oropharyngeal candidiasis. A constant concern in these patients is relapse, which is dependent on the degree of immunosuppression commonly seen after topical therapy, rather than with systemic azole therapy. Candida esophagitis (CE) is also an important concern since it occurs in more than 10% of patients with AIDS and can lead to a decrease in oral intake and associated weight loss. Fluconazole has become the most widely used antifungal in the management of mucosal candidiasis. However, itraconazole and posaconazole have similar clinical response rates as fluconazole and are also effective alternative agents. In patients with fluconazole-refractory mucosal candidiasis, treatment options now include itraconazole solution, voriconazole, posaconazole, and the newer echinocandins (caspofungin, micafungin, and anidulafungin).Keywords: oropharyngeal candidiasis, esophageal candidiasis, HAART, antifungal agents, HIV, AIDS
format	article
author	Jose A Vazquez
author_facet	Jose A Vazquez
author_sort	Jose A Vazquez
title	Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection
title_short	Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection
title_full	Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection
title_fullStr	Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection
title_full_unstemmed	Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection
title_sort	optimal management of oropharyngeal and esophageal candidiasis in patients living with hiv infection
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/d7d735c98a554681a08b12e8d0ddfc08
work_keys_str_mv	AT joseavazquez optimalmanagementoforopharyngealandesophagealcandidiasisinpatientslivingwithhivinfection
_version_	1718400020929052672

Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection

Ejemplares similares